Approval based on WAYPOINT Phase III results demonstrating reduced nasal polyp severity and nasal congestion, near-elimination of the need for surgery and significantly reduced systematic ...

AstraZeneca and Amgen's Tezspire (tezepelumab) has been approved in the European Union (EU) as an add-on therapy with ...

The FDA has approved Tezspire (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with ...

The nasal polyps market presents opportunities with multiple pipeline drugs in various development stages, targeting novel treatment approaches. Focused efforts by key players like AstraZeneca ...

Investing.com -- AstraZeneca and Amgen have received European Union approval for Tezspire as an add-on therapy for adults ...

(Alliance News) - AstraZeneca PLC on Wednesday said its drug Tezspire has been approved in the European Union for the treatment of adult patients with chronic rhinosinusitis with nasal polyps.

Drugmaker AstraZeneca said on Wednesday that its chronic rhinosinusitis with nasal polyps treatment, Tezspire, has been ...

Patients with chronic rhinosinusitis with nasal polyps and uncontrolled asthma experienced greater improvements in lung ...

The FDA approved tezepelumab-ekko (TEZSPIRE; AstraZeneca/Amgen) on Friday as an add-on maintenance treatment in patients aged ...

Amgen and AstraZeneca’s Tezspire (tezepelumab-ekko) gains FDA approval as an add-on maintenance therapy for patients aged 12 and older with inadequately controlled chronic rhinosinusitis with nasal ...

Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...

October 2025 Tezspire approved in the US for chronic rhinosinusitis with nasal polyps Approval broadens indication for Tezspire to a second disease characterised by epithelial-driven inflammationAstra ...